Why the Open Payments Program Is Likely to Provide Systematic and Transparent Data on Financial Relationships with Industry - 21/08/16
Doi : 10.1016/j.amjmed.2016.01.051
William Fleischman, MD a, Joseph S. Ross, MD, MHS a, b, c, d
a Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, Conn
b Center for Outcomes Research (CORE), Yale-New Haven Hospital, New Haven, Conn
c Department of Health Policy and Management, Yale School of Public Health, New Haven, Conn
d Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, New Haven, Conn
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflict of Interest: As part of his fellowship, WF serves as a volunteer researcher at the Centers of Medicare and Medicaid Services' (CMS) Center for Program Integrity, the center that administers the Open Payments program. JSR receives support through Yale University from CMS to develop and maintain performance measures that are used for public reporting, from Medtronic, Inc. and Johnson and Johnson to develop methods of clinical trial data sharing, from the Blue Cross Blue Shield Association to better understand medical technology evidence generation, and from the Food and Drug Administration to develop methods for postmarket surveillance of medical devices. |
|
| Authorship: WF drafted the letter; JSR critically revised it. |
© 2016
Elsevier Inc. Tous droits réservés.
Vol 129 - N° 9
P. e193 - septembre 2016 Retour au numéro
Article précédent
- A Rare Diagnosis of a Thyroid Mass
- Divya Akshintala, Bhanu T. Paturi, Jijun Liu, Vamsi K. Emani
- The Reply
- Hani A. Alhamoud, Ramzi Dudum, Heather A. Young, Brian G. Choi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?